Royce & Associates LP Trims Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Royce & Associates LP lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 55.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,000 shares of the company's stock after selling 188,000 shares during the period. Royce & Associates LP owned approximately 0.07% of Hims & Hers Health worth $3,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. State Street Corp raised its holdings in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after purchasing an additional 206,078 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock worth $79,029,000 after purchasing an additional 482,177 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock worth $63,446,000 after purchasing an additional 883,230 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Hims & Hers Health by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock worth $43,448,000 after purchasing an additional 129,416 shares during the last quarter. Finally, Yong Rong HK Asset Management Ltd purchased a new position in shares of Hims & Hers Health during the fourth quarter worth $41,104,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Remove Ads

Hims & Hers Health Price Performance

HIMS traded up $1.90 on Friday, reaching $34.77. 49,657,012 shares of the company's stock were exchanged, compared to its average volume of 13,835,924. The stock has a market cap of $7.72 billion, a PE ratio of 79.02 and a beta of 1.37. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The stock's fifty day moving average price is $39.21 and its 200-day moving average price is $28.79.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $27.97, for a total transaction of $483,964.91. Following the transaction, the insider now directly owns 193,601 shares of the company's stock, valued at $5,415,019.97. The trade was a 8.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick Harrison Carroll sold 23,287 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the transaction, the insider now directly owns 209,661 shares in the company, valued at $7,193,468.91. This trade represents a 10.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,015,547 shares of company stock worth $36,146,450. 17.71% of the stock is owned by insiders.

Analysts Set New Price Targets

HIMS has been the topic of several analyst reports. Bank of America raised their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research report on Tuesday, March 18th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Leerink Partners raised their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and raised their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.